TY - JOUR
T1 - Pharmacogenetics and personalized medicine
T2 - The future for drug prescribing
AU - Mitri, Zahi
AU - Esmerian, Maria O.
AU - Simaan, Joseph A.
AU - Sabra, Ramzi
AU - Zgheib, Nathalie Khoueiry
PY - 2010/4/1
Y1 - 2010/4/1
N2 - Pharmacogenetics, the study of interindividual variations in DNA sequence related to drug response, aims at the optimization of treatment regimens based on each patient's unique genetic makeup. Currently, there is a trend towards moving away from the concept of "one drug fits all" to a rather more individualized and personalized medicine. The goal is to define the appropriate drug dose that maximizes efficacy and minimizes toxicity in each individual patient. An example of genotyping for CYP2C9 genetic polymorphisms in patients receiving oral anticoagulants is provided. In spite of its inherent challenges, we hope that pharmacogenetic research and clinical applications expand to improve healthcare outcomes in Lebanon and worldwide.
AB - Pharmacogenetics, the study of interindividual variations in DNA sequence related to drug response, aims at the optimization of treatment regimens based on each patient's unique genetic makeup. Currently, there is a trend towards moving away from the concept of "one drug fits all" to a rather more individualized and personalized medicine. The goal is to define the appropriate drug dose that maximizes efficacy and minimizes toxicity in each individual patient. An example of genotyping for CYP2C9 genetic polymorphisms in patients receiving oral anticoagulants is provided. In spite of its inherent challenges, we hope that pharmacogenetic research and clinical applications expand to improve healthcare outcomes in Lebanon and worldwide.
UR - http://www.scopus.com/inward/record.url?scp=77954926600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954926600&partnerID=8YFLogxK
M3 - Review article
C2 - 20549897
AN - SCOPUS:77954926600
SN - 0023-9852
VL - 58
SP - 101
EP - 104
JO - Journal Medical Libanais
JF - Journal Medical Libanais
IS - 2
ER -